Loading...
OTCM
CALA
Market cap0kUSD
Oct 07, Last price  
0.00USD
1D
0.00%
1Q
-66.67%
Jan 2017
-100.00%
IPO
-100.00%
Name

Calithera Biosciences Inc

Chart & performance

D1W1MN
OTCM:CALA chart
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
24.82%
Rev. gr., 5y
-7.40%
Revenues
0
-100.00%
0000025,955,00022,254,000009,750,0000
Net income
-19m
L-83.61%
-7,975,000-12,377,000-21,712,000-32,644,000-38,004,000-27,826,000-51,472,000-86,346,000-88,523,000-115,088,000-18,866,000
CFO
-44m
L-34.23%
-6,990,000-11,837,000-19,231,000-29,933,000-31,025,00013,751,000-64,842,000-78,745,000-84,312,000-66,300,000-43,608,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.

Key people

Susan Molineaux
President, Chief Executive Officer, Co-Founder, Director · since 2010
Stephanie Wong
Chief Financial Officer, Secretary · since 2023
Emil Kuriakose
Chief Medical Officer · since 2021
Keith Orford
Director · since 2021
Sunil Agarwal
Independent Director · since 2015
Scott Garland
Independent Director · since 2020
Suzy Jones
Independent Director · since 2016
Deepika Pakianathan
Lead Independent Director · since 2017
Blake Wise
Independent Director · since 2017
H. Ward Wolff
Independent Director · since 2014
URL
https://www.calithera.com/
IPO date
Oct 02, 2014
Employees
8
Domiciled in
US
Incorporated in
US
Legal address
C/O The Corporation Trust Company
Corporation Trust Center
1209 Orange Street
Wilmington, DE 19801
US
Headquarters
343 Oyster Point Boulevard
Suite 200
South San Francisco, CA 94080
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT